表紙
市場調査レポート

Protagonist Therapeutics Inc.の製品パイプライン分析

Protagonist Therapeutics Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 321342
出版日 ページ情報 英文 24 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
Protagonist Therapeutics Inc.の製品パイプライン分析 Protagonist Therapeutics Inc. - Product Pipeline Review - 2015
出版日: 2015年08月31日 ページ情報: 英文 24 Pages
概要

Protagonist Therapeutics Inc.は米国に本社をおくバイオテクノロジー企業で、ジスルフィド結合ペプチドおよび抗体代替物質など中枢神経系、胃腸系、感染症、腫瘍、免疫、代謝系の疾患に対する治療薬開発のための化合物の開発を行っています。

当レポートでは、Protagonist Therapeutics Inc. における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Protagonist Therapeutics Inc. の基本情報

  • Protagonist Therapeutics Inc. の概要
  • 主要情報
  • 企業情報

Protagonist Therapeutics Inc. :R&Dの概要

  • 主な治療範囲

Protagonist Therapeutics Inc. :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Protagonist Therapeutics Inc. :パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ

Protagonist Therapeutics Inc. :薬剤プロファイル

  • Peptide Agonists of Hepcidin for Beta-Thalassemia and Juvenile Hemochromatosis
  • Synthetic Peptides to Antagonize Alpha-4 Beta-7 Integrin for IBD
  • Synthetic Peptides to Block Nav 1.7 Ion Channel for Pain
  • Synthetic Peptides To Inhibit Interleukin-6 for Inflammatory and Autoimmune Diseases
  • Synthetic Peptides to Target IL-23 and IL-23R for GI Disorders
  • Peptides for Irritable Bowel Syndrome and Inflammatory Bowel Disease
  • Synthetic Peptide for Diabetes, Cancer, Gastrointestinal Disorders and Infectious Disease
  • Synthetic Peptides for Gastrointestinal Disorders

Protagonist Therapeutics Inc. :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Protagonist Therapeutics Inc. :最新のパイプライン情報

Protagonist Therapeutics Inc. :本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07529CDB

Summary

Global Markets Direct's, 'Protagonist Therapeutics Inc. - Product Pipeline Review - 2015', provides an overview of the Protagonist Therapeutics Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Protagonist Therapeutics Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Protagonist Therapeutics Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Protagonist Therapeutics Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Protagonist Therapeutics Inc.'s pipeline products

Reasons to buy

  • Evaluate Protagonist Therapeutics Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Protagonist Therapeutics Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Protagonist Therapeutics Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Protagonist Therapeutics Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Protagonist Therapeutics Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Protagonist Therapeutics Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Protagonist Therapeutics Inc. Snapshot
    • Protagonist Therapeutics Inc. Overview
    • Key Information
    • Key Facts
  • Protagonist Therapeutics Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Protagonist Therapeutics Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Protagonist Therapeutics Inc. - Pipeline Products Glance
    • Protagonist Therapeutics Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Protagonist Therapeutics Inc. - Drug Profiles
    • Peptide Agonists of Hepcidin for Beta-Thalassemia and Juvenile Hemochromatosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PTG-100
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptides to Block Nav 1.7 Ion Channel for Neuropathic Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptides To Inhibit Interleukin-6 for Crohn's Disease and Rheumatoid Arthritis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptides to Target IL-23R for Crohn's Disease and Ulcerative colitis
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Protagonist Therapeutics Inc. - Pipeline Analysis
    • Protagonist Therapeutics Inc. - Pipeline Products by Target
    • Protagonist Therapeutics Inc. - Pipeline Products by Route of Administration
    • Protagonist Therapeutics Inc. - Pipeline Products by Molecule Type
    • Protagonist Therapeutics Inc. - Pipeline Products by Mechanism of Action
  • Protagonist Therapeutics Inc. - Recent Pipeline Updates
  • Protagonist Therapeutics Inc. - Dormant Projects
  • Protagonist Therapeutics Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Protagonist Therapeutics Inc., Key Information
  • Protagonist Therapeutics Inc., Key Facts
  • Protagonist Therapeutics Inc. - Pipeline by Indication, 2015
  • Protagonist Therapeutics Inc. - Pipeline by Stage of Development, 2015
  • Protagonist Therapeutics Inc. - Monotherapy Products in Pipeline, 2015
  • Protagonist Therapeutics Inc. - Preclinical, 2015
  • Protagonist Therapeutics Inc. - Pipeline by Target, 2015
  • Protagonist Therapeutics Inc. - Pipeline by Route of Administration, 2015
  • Protagonist Therapeutics Inc. - Pipeline by Molecule Type, 2015
  • Protagonist Therapeutics Inc. - Pipeline Products by Mechanism of Action, 2015
  • Protagonist Therapeutics Inc. - Recent Pipeline Updates, 2015
  • Protagonist Therapeutics Inc. - Dormant Developmental Projects,2015
  • Protagonist Therapeutics Inc., Subsidiaries

List of Figures

  • Protagonist Therapeutics Inc. - Pipeline by Top 10 Indication, 2015
  • Protagonist Therapeutics Inc. - Pipeline by Top 10 Target, 2015
  • Protagonist Therapeutics Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Protagonist Therapeutics Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Protagonist Therapeutics Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top